Anticancer therapeutics: A surge of new developments increasingly target tumor and stroma
Authors:
- Henk J. BroxtermanHBHenk J. Broxterman
- Nafsika H. GeorgopapadakouNGNafsika H. Georgopapadakou
- 31 October 2007
- journal article
- Published by Elsevier in Drug Resistance Updates
- Vol. 10 (4-5) , 182-193
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Thrombospondin-based antiangiogenic therapyMicrovascular Research, 2007
- Anti-angiogenic peptides identified in thrombospondin type I domainsBiochemical and Biophysical Research Communications, 2007
- Tissue-specific and reversible RNA interference in transgenic miceNature Genetics, 2007
- The role of galectin-3 in cancer drug resistanceDrug Resistance Updates, 2007
- Hypoxia-Inducible Factors, Stem Cells, and CancerCell, 2007
- HIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional ActivityCancer Cell, 2007
- Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit from cytokinesisThe EMBO Journal, 2007
- Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapyProceedings of the National Academy of Sciences, 2006
- Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressivenessNature Medicine, 2006
- RETRACTED: Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesisCancer Cell, 2003